All News

chalkboard disparities black white

Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis

d Bella Mehta, MBBS, MS

Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.  

Read Article
A closer Look at PsA Measures and Outcomes

Measuring Disease Activity in PsA: Dr. Eric Ruderman

d Eric Ruderman, MD

In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month. 

Read Article
pills-384846_640%20%281%29.jpg

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

d Richard Conway, MBBChBAO, PhD

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

Read Article
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20 https://t.co/5Qg3HRkQyW

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

Dr. Rachel Tate ( @uptoTate) reviews outpatient billing and coding pearls presented at a session at the #ACR20 meeting. https://t.co/66YbqXcncr https://t.co/PDdVKfNJYd

Links:

Dr. John Cush RheumNow ( View Tweet)
Check on Pneumococcal Vaccination: Dr. Janet Pope ( @Janetbirdope) #ACR20 https://t.co/D9EQ3Tl2Ot https://t.co/Zn8IVorCcs

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @CreakyJoints : .@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20. How important is empathy in your doctor-patient relationship? https://t.co/dnJ3f8QouE
Dr. John Cush RheumNow ( View Tweet)
Revisit our #ACR20 coverage. Listen to our Day 3 part II recap. Follow the link below or find us on Apple/Android podcasts. https://t.co/1TcXfU5TMg https://t.co/hn298mJIUL

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @SattuiSEMD :L06: Mavrilimumab in #GCA Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new/relapsing/ref pts, No diff in AE

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets "RT @DrMiniDey : RITAZAREM trial long-term f/u -RTX vs AZA after RTX-induced remission in ANCA -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 https://t.co/cKV7qM77og

Links:

Dr. John Cush RheumNow ( View Tweet)

Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction https://t.co/jpZC4KFygJ https://t.co/k7WFNQg9AY

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis. https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx

Links:

Dr. John Cush RheumNow ( View Tweet)
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20 https://t.co/5Qg3HRkQyW https://t.co/x0iQ6XX3eJ

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : Wonder if you can predict development of clinical RA in those at risk either w/ a - +RF or +CCP - Relevant sxs w/ or w/o abs - 1st deg relatives do RA pts? #ACR20 https://t.co/xVZHxL35UY

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

Dr. John Cush RheumNow ( View Tweet)

New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20 https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets "RT @drdavidliew : This - very cool. Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see! #ACR20 ABST1995 @RheumNow https://t.co/cE3gQar0zo https://t.co/bmGnrMGaq3

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×